When used for monitoring the response to chemotherapy, the RAD51 assay can significantly distinguish cancers responsive to carboplatin (p = 0.02): the benefit of its administration was maintained also in the multivariate analysis after adjustment for predefined clinical–pathological parameters (OR = 7.52, 95% CI 2.21–25.61, p = 0.001). Here, RAD51 is linked to cancer.